Skip to Content

How is Inflectra different from Remicade?

Answers (1)

Official Answer by 5 May 2016

Inflectra (infliximab-dyyb) by Celltrion is the second U.S. biosimilar approved by the FDA. Inflectra is classified as a tumor necrosis factor (TNF) blocker and is biosimilar to Janssen’s Remicade (infliximab), originally approved in 1998.

A biosimilar must have no clinically meaningful safety or effectiveness differences from the reference product, but it is not considered identical like a generic product.

Inflectra can be prescribed for the same uses as Remicade, including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis (spine arthritis), ulcerative colitis, psoriatic arthritis, and plaque psoriasis.

Votes: +1 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 18 days ago 1 answerFAQ by

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 15 days ago 1 answerFAQ by

How do you use the ProAir Digihaler?

Updated 15 days ago 1 answerFAQ by

How many biosimilars have been approved in the United States?

Updated 14 days ago 1 answerFAQ by